CA3252232A1 - METHODS OF TREATMENT OF SEGMENTAL AND FOCAL GLOMERULOSCLEROSIS WITH ATRASENTAN - Google Patents

METHODS OF TREATMENT OF SEGMENTAL AND FOCAL GLOMERULOSCLEROSIS WITH ATRASENTAN

Info

Publication number
CA3252232A1
CA3252232A1 CA3252232A CA3252232A CA3252232A1 CA 3252232 A1 CA3252232 A1 CA 3252232A1 CA 3252232 A CA3252232 A CA 3252232A CA 3252232 A CA3252232 A CA 3252232A CA 3252232 A1 CA3252232 A1 CA 3252232A1
Authority
CA
Canada
Prior art keywords
subject
atrasentan
weeks
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3252232A
Other languages
English (en)
French (fr)
Inventor
Andrew James KING
Vincent Wai Yip TONG
Marianne CAMARGO
Original Assignee
Chinook Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Therapeutics Inc filed Critical Chinook Therapeutics Inc
Publication of CA3252232A1 publication Critical patent/CA3252232A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3252232A 2022-05-19 2023-05-18 METHODS OF TREATMENT OF SEGMENTAL AND FOCAL GLOMERULOSCLEROSIS WITH ATRASENTAN Pending CA3252232A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263343574P 2022-05-19 2022-05-19
US63/343,574 2022-05-19
PCT/US2023/022681 WO2023225163A1 (en) 2022-05-19 2023-05-18 Methods of treating focal segmental glomerulosclerosis with atrasentan

Publications (1)

Publication Number Publication Date
CA3252232A1 true CA3252232A1 (en) 2023-11-23

Family

ID=88836135

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3252232A Pending CA3252232A1 (en) 2022-05-19 2023-05-18 METHODS OF TREATMENT OF SEGMENTAL AND FOCAL GLOMERULOSCLEROSIS WITH ATRASENTAN

Country Status (10)

Country Link
US (1) US20250352511A1 (enExample)
EP (1) EP4525857A4 (enExample)
JP (1) JP2025517355A (enExample)
KR (1) KR20250013180A (enExample)
CN (1) CN119325377A (enExample)
AU (1) AU2023271840A1 (enExample)
CA (1) CA3252232A1 (enExample)
IL (1) IL316349A (enExample)
MX (1) MX2024013985A (enExample)
WO (1) WO2023225163A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
US20170014386A1 (en) * 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
IL294410B2 (en) * 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
HRP20260121T1 (hr) * 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije

Also Published As

Publication number Publication date
JP2025517355A (ja) 2025-06-05
EP4525857A1 (en) 2025-03-26
AU2023271840A1 (en) 2024-10-31
EP4525857A4 (en) 2026-05-20
KR20250013180A (ko) 2025-01-31
IL316349A (en) 2024-12-01
MX2024013985A (es) 2025-02-10
US20250352511A1 (en) 2025-11-20
CN119325377A (zh) 2025-01-17
WO2023225163A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
US11998526B2 (en) Methods of improving renal function
US20230270718A1 (en) Methods of treating diabetic kidney disease
US20250352511A1 (en) Methods of treating focal segmental glomerulosclerosis with atrasentan
US20220304979A1 (en) Methods of reducing disease flares
ES3062063T3 (en) A pharmaceutically acceptable salt of atrasentan for use in a method of treating iga nephropathy
HK40059453A (en) Methods of treating iga nephropathy with atrasentan
HK40094573A (en) Methods of treating iga nephropathy with atrasentan
BR122023026537A2 (pt) Uso de atrasentan para tratar nefropatia por iga
KR20250099171A (ko) 엔도텔린 수용체 길항제 및 april 결합 항체를 사용한 iga 신장병증의 치료

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241105

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250203

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250203

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250423

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421